In the case of tumor cells with deficiency in BRCA1 or BRCA2, loss of CSB expression would also predict that these cancer cells would not be able to depend upon BIR for survival and might turn to different salvage repair pathways such as alternative end joining, which in turn could be targeted. The gene discussed is ERCC6; the disease is cancer.